TheraRadar
← Back
Data updated: Jun 28, 2026

NE RX PHARMA

Generics

NE RX PHARMA is a generic drug manufacturer focused on Cardiovascular, Neurology, Ophthalmology.

2022
Since
5
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

Upcoming FDA Decisions

Full Calendar →
Aug 2, 2026 — RP1 (vusolimogene oderparepvec) + nivolumab
22d
Aug 19, 2026 — Garetosmab
Oct 9, 2026 — Tecentriq (atezolizumab) + chemotherapy

NE RX PHARMA's Key Drugs

NE RX PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NE RX PHARMA's Recent FDA Approvals

New NDA/BLA approvals for NE RX PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NE RX PHARMA's Therapeutic Areas

NE RX PHARMA's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 40%
2 drugs
Neurology 20%
1 drugs
Ophthalmology 20%
1 drugs
Gastroenterology 20%
1 drugs

NE RX PHARMA's Top Competitors

NE RX PHARMA's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Novartis, and VALIDUS PHARMS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NE RX PHARMA Pipeline Snapshot

Active clinical trials for NE RX PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling